Biogen enrolls patients in new MS trial - Boston Business Journal:

http://safershopping.org/consumer/faq.htm
The trial, called ADVANCE, will determines the efficacy and safetyof Biogen’s drug called PEGylated interferon beta-1a, in reducing relapse ratee in patients with multiple sclerosizs (RMS). The global studyt will enroll morethan 1,200 patientx with RMS between the ages of 18 and 55. The study’z goal is to determine whether the drug reduces the annualized relapsw rate in patients with RMS at one The study will alsoexamine if, over the potential treatment can slow diseasw progression and lead to a decreas e in the number of a certain kind of braib lesions commonly seen in MS patients.
The treatmenyt is a combination ofInterferon beta-1a, which has been used successfully to treat MS for more than 10 and PEGylation, which can extend the amount of time a drug remainw in a patient’s system. If the triapl is successful, the treatment has the potential to reduce the frequencg of treatment injections and provide patients with an effective and more conveniengtdosing option. Biogen’s (NASDAQ: BIIB) stocj was trading at in $49.33 in morning tradingb on Monday, down from the previou close of $51.67.